Unaudited Interim Results to 30 June 2025

AI SummaryClose X

ProBiotix Health PLC reported unaudited interim results for the six months ending June 30, 2025, featuring a 33% increase in gross revenue to £1.34 million, up from £1.01 million in H1 2024. Gross profit also increased by 33% to £748,000, compared to £564,000 in the prior year. The company reduced its EBITDA loss, excluding share-based payments, by 52% to £112,000 from a £232,000 loss in H1 2024. Sales outside the USA grew significantly, increasing by 127% to £584,000 from £257,000. ProBiotix also reported a strong cash balance of £1.3 million, a notable increase from £865,000 in H1 2024. The net loss for the period reduced by 42% to £0.150 million (2024: £0.261 million).

Disclaimer*

UK 100

Latest directors dealings